GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Return-on-Tangible-Asset

FSD Pharma (FSD Pharma) Return-on-Tangible-Asset : -41.35% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. FSD Pharma's annualized Net Income for the quarter that ended in Dec. 2023 was $-5.29 Mil. FSD Pharma's average total tangible assets for the quarter that ended in Dec. 2023 was $12.80 Mil. Therefore, FSD Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -41.35%.

The historical rank and industry rank for FSD Pharma's Return-on-Tangible-Asset or its related term are showing as below:

HUGE' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1433.33   Med: -114.22   Max: -67.04
Current: -103.19

During the past 9 years, FSD Pharma's highest Return-on-Tangible-Asset was -67.04%. The lowest was -1433.33%. And the median was -114.22%.

HUGE's Return-on-Tangible-Asset is ranked worse than
91.49% of 1081 companies
in the Drug Manufacturers industry
Industry Median: 1.83 vs HUGE: -103.19

FSD Pharma Return-on-Tangible-Asset Historical Data

The historical data trend for FSD Pharma's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FSD Pharma Return-on-Tangible-Asset Chart

FSD Pharma Annual Data
Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only -120.13 -115.76 -93.71 -64.56 -93.02

FSD Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.59 -175.54 -126.02 -30.86 -41.35

Competitive Comparison of FSD Pharma's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, FSD Pharma's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FSD Pharma's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, FSD Pharma's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where FSD Pharma's Return-on-Tangible-Asset falls into.



FSD Pharma Return-on-Tangible-Asset Calculation

FSD Pharma's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-17.902/( (26.371+12.119)/ 2 )
=-17.902/19.245
=-93.02 %

FSD Pharma's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-5.292/( (13.48+12.119)/ 2 )
=-5.292/12.7995
=-41.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


FSD Pharma  (NAS:HUGE) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


FSD Pharma Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of FSD Pharma's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


FSD Pharma (FSD Pharma) Business Description

Traded in Other Exchanges
Address
199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9
FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.